117 related articles for article (PubMed ID: 15698944)
21. The systemic inflammatory response to exercise in adults with cystic fibrosis.
Ionescu AA; Mickleborough TD; Bolton CE; Lindley MR; Nixon LS; Dunseath G; Luzio S; Owens DR; Shale DJ
J Cyst Fibros; 2006 May; 5(2):105-12. PubMed ID: 16403491
[TBL] [Abstract][Full Text] [Related]
22. Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia.
Jensen PØ; Moser C; Kharazmi A; Presler T; Koch C; Høiby N
J Cyst Fibros; 2006 Aug; 5(3):145-51. PubMed ID: 16503423
[TBL] [Abstract][Full Text] [Related]
23. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M
J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
Etherington C; Hall M; Conway S; Peckham D; Denton M
J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
[TBL] [Abstract][Full Text] [Related]
25. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation.
Downey DG; Brockbank S; Martin SL; Ennis M; Elborn JS
Pediatr Pulmonol; 2007 Aug; 42(8):729-35. PubMed ID: 17588254
[TBL] [Abstract][Full Text] [Related]
26. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis.
Jarad NA; Giles K
Chron Respir Dis; 2008; 5(1):29-33. PubMed ID: 18303099
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary infection in mild variant cystic fibrosis: implications for care.
Lording A; McGaw J; Dalton A; Beal G; Everard M; Taylor CJ
J Cyst Fibros; 2006 May; 5(2):101-4. PubMed ID: 16426904
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.
Sequeiros IM; Jarad N
Chron Respir Dis; 2012 Feb; 9(1):9-16. PubMed ID: 22308550
[TBL] [Abstract][Full Text] [Related]
31. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.
Karadag F; Kirdar S; Karul AB; Ceylan E
Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305
[TBL] [Abstract][Full Text] [Related]
32. Bioelectric impedance spectroscopy underestimates fat-free mass compared to dual energy X-ray absorptiometry in incurable cancer patients.
Ellegård LH; Ahlén M; Körner U; Lundholm KG; Plank LD; Bosaeus IG
Eur J Clin Nutr; 2009 Jun; 63(6):794-801. PubMed ID: 18478025
[TBL] [Abstract][Full Text] [Related]
33. Plasma ghrelin and leptin in adult cystic fibrosis patients.
Cohen RI; Tsang D; Koenig S; Wilson D; McCloskey T; Chandra S
J Cyst Fibros; 2008 Sep; 7(5):398-402. PubMed ID: 18353734
[TBL] [Abstract][Full Text] [Related]
34. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis.
Downey DG; Martin SL; Dempster M; Moore JE; Keogan MT; Starcher B; Edgar J; Bilton D; Elborn JS
Pediatr Pulmonol; 2007 Mar; 42(3):216-20. PubMed ID: 17238189
[TBL] [Abstract][Full Text] [Related]
35. Temocillin in cystic fibrosis: a retrospective pilot study.
Kent L; Bradley JM; France M; Döring G; Carryn S; Bradbury I; Rendall J; Jones A; Elborn JS
J Cyst Fibros; 2008 Nov; 7(6):551-4. PubMed ID: 18706868
[TBL] [Abstract][Full Text] [Related]
36. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.
Ferroni A; Guillemot D; Moumile K; Bernede C; Le Bourgeois M; Waernessyckle S; Descamps P; Sermet-Gaudelus I; Lenoir G; Berche P; Taddei F
Pediatr Pulmonol; 2009 Aug; 44(8):820-5. PubMed ID: 19598278
[TBL] [Abstract][Full Text] [Related]
37. Recurrent pulmonary exacerbations are associated with low fat free mass and low bone mineral density in young adults with cystic fibrosis.
Alicandro G; Bisogno A; Battezzati A; Bianchi ML; Corti F; Colombo C
J Cyst Fibros; 2014 May; 13(3):328-34. PubMed ID: 24291530
[TBL] [Abstract][Full Text] [Related]
38. Predictors of mortality in adults with cystic fibrosis.
Courtney JM; Bradley J; Mccaughan J; O'Connor TM; Shortt C; Bredin CP; Bradbury I; Elborn JS
Pediatr Pulmonol; 2007 Jun; 42(6):525-32. PubMed ID: 17469153
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammation markers during weight loss.
Salas-Salvadó J; Bulló M; García-Lorda P; Figueredo R; Del Castillo D; Bonada A; Balanzà R
Int J Obes (Lond); 2006 Dec; 30(12):1714-20. PubMed ID: 16652132
[TBL] [Abstract][Full Text] [Related]
40. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
